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Abstract
Steroid-refractory (SR) acute graft-versus-host disease (aGvHD) remains a signiﬁcant complication after allogeneic hematopoietic
cell transplantation. Systemic corticosteroids are ﬁrst-line therapy for aGvHD, but apart from ruxolitinib, there are no approved
treatments for SR aGvHD. Vedolizumab is approved for treatment of ulcerative colitis and Crohn’s disease, and may be effective
for treatment of SR intestinal aGvHD. We conducted a phase 2a trial (NCT02993783) to evaluate the clinical efﬁcacy, tolerability,
and safety of vedolizumab 300 and 600 mg for SR intestinal aGvHD. This study was terminated before full enrollment was
completed because early results failed to demonstrate positive proof-of-concept in efﬁcacy. Before termination, 17 participants had
enrolled and an early response in intestinal aGvHD was observed in 11 and eight participants at days 15 and 28, respectively. All
adverse events observed were consistent with those expected in a population with SR intestinal aGvHD. Overall, vedolizumab did
not meet the primary efﬁcacy endpoint (overall response at day 28), likely owing to premature study drug discontinuation, lack of
efﬁcacy, and the competing risks inherent with a population with advanced SR intestinal aGvHD. Nevertheless, this study
provides valuable insights into the considerations needed when conducting studies in patients with SR intestinal aGvHD.

Introduction
Allogeneic hematopoietic cell transplantation is an important and potentially curative therapy for many hematologic

Supplementary information The online version contains
supplementary material available at https://doi.org/10.1038/s41409021-01356-0.

malignancies, but carries the signiﬁcant risk of graft-versushost disease (GvHD) [1, 2]. Acute GvHD (aGvHD), which
generally occurs in the ﬁrst few months after allogeneic
hematopoietic stem cell transplantation, typically involves
the skin, liver, and/or intestine [2–4].
After conventional allogeneic hematopoietic cell transplantation, the incidence of aGvHD ranges from 10% to
80% (dependent on certain clinical risk factors) in patients
receiving T-cell-replete allogeneic grafts, despite standard
measures of prophylaxis [5–7].

* Yngvar Fløisand
yﬂoisan@ous-hf.no

6

Center for International Blood and Marrow Transplant Research
(CIMBTR) Minneapolis Campus, Minneapolis, MN, USA

1

Department of Haematology, Oslo University Hospital,
Rikshospitalet, Oslo, Norway

7

Hematology Oncology, Cellular and Gene Therapy, ICON
Clinical Research Service, New York, NY, USA

2

Centre for Cancer Cell Reprogramming, Department of Molecular
Cell Biology, Oslo University Hospital, Oslo, Norway

8

Hematology Department, AP-HP, Hôpital Saint-Antoine,
Sorbonne Université, and INSERM UMRs 938, Paris, France

3

Division of Oncology, Washington University School of
Medicine, St. Louis, MO, USA

9

CHU de Lille, Univ Lille, INSERM U1286, Inﬁnite, Lille, France

10

Millennium Pharmaceuticals Inc, Cambridge, MA, USA

CHU de l’Hôtel-Dieu, service d’hématologie clinique, place A.
Ricordeau, Nantes, France

11

Hematopoietic Cell Transplant and Cellular Therapy Program,
Massachusetts General Hospital, Boston, MA, USA

4

5

AZ Sint-Jan Brugge-Oostende, Brugge, Belgium

2478

First-line therapy for patients who develop aGvHD is systemic corticosteroids, but these are effective only in ~50% of
patients, with durable responses observed in only one-third
[8, 9]. Apart from ruxolitinib, which is associated with cytopenias, there are no other approved treatments for steroidrefractory (SR) aGvHD, which is associated with historical
2-year survival rates of <20% [10–12]. Furthermore, there are
no targeted treatments for intestinal aGvHD, for the majority
of morbidity and mortality associated with SR aGvHD [13].
Vedolizumab, a humanized immunoglobulin G1 monoclonal antibody directed against the α4β7 integrin expressed on lymphocytes and implicated in gastrointestinal
(GI) trafﬁcking, was developed for the treatment of
moderate–severe ulcerative colitis and Crohn’s disease
[14–16]. Vedolizumab inhibits the interaction between
α4β7 integrin and the mucosal addressin cell adhesion
molecule-1 (MAdCAM-1), preventing the migration of
gut-homing leukocytes into the GI mucosa [17–20]. Preclinical studies have suggested that blocking this interaction may prevent intestinal aGvHD, and multiple series
have suggested that vedolizumab may have efﬁcacy for the
treatment of SR intestinal aGvHD [21–23].
Here we present data from a phase 2a clinical trial
(NCT02993783), which prospectively investigated the
clinical efﬁcacy, tolerability, and safety of vedolizumab for
the treatment of SR intestinal aGvHD.

Methods
Study design
This was a phase 2a, randomized, parallel, open-label study
with two dose groups evaluating the clinical efﬁcacy, tolerability, and safety of vedolizumab (Hospira McPherson,
KS, USA) IV for treatment of SR intestinal aGvHD.

Recruitment and consent
Participants were recruited and enrolled from the investigator’s practice or on referrals from other physicians. If
alternative recruitment strategies were employed (such as
advertisement) these were reviewed by the institutional
review board (IRB)/independent ethics committee (IEC).
All participants provided written informed consent before
any study-required procedures were conducted, unless such
procedure formed part of their standard of care.

Eligibility criteria
Participants were 18 years or older, had undergone a ﬁrst
allogeneic hematopoietic cell transplant, and had developed
SR intestinal aGvHD (worsening or no improvement after
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5–7 days of methylprednisolone 2 mg/kg/day or equivalent,
or lack of a complete response after 14 days of methylprednisolone 2 mg/kg/day or equivalent (Supplementary
Table 1)). Participants who developed intestinal aGvHD
while receiving systemic therapy for other aGvHD organ
manifestations were also eligible after 5–7 days, even if
intestinal aGvHD had not been present for the entire duration. Participants were required to have Grade B–D aGvHD
with intestinal involvement and an Eastern Cooperative
Oncology Group (ECOG) Performance Status of 0–3.
Patients who had received any systemic agents beyond
corticosteroids for the treatment of aGvHD were excluded.
Detailed inclusion and exclusion criteria are listed in
Supplementary Table 2.

Treatments
The intravenous (IV) doses and schedule of vedolizumab
were selected based on those approved for the treatment of
ulcerative colitis and Crohn’s disease (300 mg IV every
8 weeks) [14]. Because SR intestinal aGvHD may require
higher doses of vedolizumab to achieve target saturation,
owing to hypoalbuminemia, a dose of vedolizumab 600 mg
IV was also evaluated [14, 16, 24, 25].
Participants were randomized 1:1 to receive 300 or 600
mg doses of vedolizumab IV on days 1, 15, 43, 71, and 99
on the basis of evidence from a previous case series [26].
Investigators used an interactive voice or web response
technology system at screening to obtain the participant
study number and randomize them to receive 300 or 600 mg
doses of vedolizumab. Participants who responded to, and
tolerated all ﬁve planned doses of vedolizumab, and who
developed recurrent symptoms of intestinal aGvHD following discontinuation of therapy were permitted to receive
additional doses of vedolizumab for up to 1 year from the
ﬁrst dose of the study drug (extension phase). Other medications considered necessary for the safety and wellbeing
of the participant were permitted at the discretion of the
investigator.

Sample size
It was intended that after ten participants had enrolled in
each dose group and had been followed through day 28,
safety, tolerability, efﬁcacy, and pharmacokinetic (PK)
results would be assessed to determine an appropriate dose
for subsequent participants. The group at the chosen dose
would have been expanded by approximately 18 additional
participants to assess the tolerability and efﬁcacy of vedolizumab further (approximately 38 patients in total were
planned for enrollment). However, early results failed to
demonstrate a positive proof-of-concept in efﬁcacy
(described below) and the trial was terminated early.

Vedolizumab for the treatment of steroid-refractory intestinal aGvHD

Study endpoints
The primary endpoints of the study were overall response
(OR) (deﬁned as either a partial response, a very good
partial response, or a complete response—Supplementary
Table 1) at day 28 and incidence of treatment-emergent
serious adverse events (TEAEs) following the administration of the ﬁrst dose of vedolizumab to day 28.
Secondary endpoints included overall survival at 6 and
12 months, complete response at day 28, intestinal OR at
day 28, and TEAEs and/or serious adverse events following
the ﬁrst dose of vedolizumab through 18 weeks after the last
dose of vedolizumab (treatment exposure period). PK
characterization of vedolizumab and the presence of antivedolizumab antibodies at baseline and at the end of the
exposure period were also performed, and durable intestinal
OR rate (intestinal OR achieved at day 28 and maintained
OR at day 43) was evaluated as an exploratory endpoint.
All participants were planned to be followed for overall
survival every 3 months until death, withdrawal of consent,
termination of study by the sponsor, or for a maximum of
1 year after the last subject was enrolled in the study.

Measurements
Severity of aGvHD was assessed at each visit using the
Blood and Marrow Transplant Clinical-Trials Network
(BMT CTN)-modiﬁed International Blood and Marrow
Transplant Research (IBMTR) database index (Supplementary Table 3) [27, 28]. The severity (Stage 0–4) of skin,
liver, and intestinal GvHD was based on aGvHD clinicalstage criteria.
Blood samples for PK analysis of vedolizumab were
collected as per the schedule outlined in Supplementary
Table 4. Vedolizumab serum concentrations were measured
by enzyme-linked immunosorbent assay with a validated
range of 0.20–8.00 μg/mL. Immunogenicity was evaluated
using blood sampling for anti-vedolizumab antibodies in
pre-dose serum on day 1, and on days 22, 71, and 99.

Statistics
A Bayesian statistical approach was planned for efﬁcacy
evaluation. An interim analysis was planned when all participants had reached day 28 (10 participants in each group). A
positive proof-of-concept in efﬁcacy was considered if the
posterior probability of day 28 OR rate >54% was at least
85% and day 28 OR rate being at least 70% was at least 75%.
Early review of patient-level data was performed ahead of the
planned analysis to assess safety, PK, and efﬁcacy data in
order to facilitate decision-making in the study.
Enrolled participants who received any dose of study
drug comprised the safety analysis set. The efﬁcacy analysis
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set included all participants from the safety analysis set who
had a baseline efﬁcacy assessment and at least one postbaseline efﬁcacy assessment. The PK analysis set comprised all participants in the safety analysis set who had at
least one post-dose PK sample collected.
Approximately 38 patients were planned for enrollment.
The sample size was based on clinical considerations and
considered sufﬁcient to determine a recommended dose and
regimen and to describe the efﬁcacy, tolerability, and safety
of vedolizumab IV.

Results
Study population
On the basis of an early review of patient-level data and the
totality of evidence available, it was concluded that the
ability to evaluate overall efﬁcacy was impaired owing to
(a) the competing risks in the population, (b) premature
discontinuation of study drug, and (c) observed mortality. It
was determined that the proportion of participants achieving
the primary efﬁcacy outcome was not expected to reach
54% and the study was terminated early (9 May 2018) by
the sponsor. Participants were recruited and followed from
28 April 2017 until study termination.
Before termination, 17 participants were enrolled and
treated at 11 sites in Belgium, France, Norway, and the
USA (Fig. 1). Of these, 13 participants completed day 28,
four participants (23.5%) completed all ﬁve planned doses
of vedolizumab (two from each dose group), and one participant entered the extension phase and received two
additional doses of vedolizumab 600 mg. The median
number of doses in each treatment group was 2.

Demographics and disease characteristics
Baseline characteristics are presented in Table 1. Overall
median age was 57 years (range, 34–74 years), with four
participants (23.5%) aged 65 years or older. Five participants
(29.4%) had a baseline ECOG Performance Status of 3.
A total of 12 participants (70.6%) had isolated intestinal
aGvHD, four (23.5%) had skin and intestinal involvement,
and one (5.9%) had liver and intestinal involvement.
Twelve participants (70.6%) had Grade C or D aGvHD
(eight Grade C aGvHD, four Grade D aGvHD). At baseline,
13 participants (76.5%) had Stage 2 or greater intestinal
aGvHD (one Stage 2, eight Stage 3, four Stage 4).

Individual participant data
Baseline disease characteristics and outcomes for each
participant are presented in Supplementary Table 5A–C. A
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Planned for enrollment (N = 38)

Randomized (N = 17)

Recruitment terminated by sponsor due to failure to
demonstrate positive proof of concept

Vedolizumab 300 mg
(n = 8)

Vedolizumab 600 mg
(n = 9)

Prematurely discontinued study drug (n = 6)
Adverse event (n = 2)
Acute respiratory distress syndrome
Adverse event
Unsatisfactory therapeutic response (n = 1)
Progression of underlying malignancy (n = 1)
Acute myeloid leukemia
Other (n = 2)
Death (aGvHD)
Withdrawal by participant

Prematurely discontinued study drug (n = 7)
Adverse event (n = 1)
Transplant-associated microangiopathy
aGvHD (n = 1)
Unsatisfactory therapeutic response (n = 3)
Other (n = 2)
Death (thrombotic microangiopathy)
Death (acute kidney failure)

Deaths (n = 4)a
Complications associated with aGvHD (n = 1)
Rectal hemorrhage
Sepsis (n = 2)
Morganella morganii (n = 1)
Polymicrobial bacteremia (n = 1)
Unknown cause (n = 1)

Deaths (n = 8)
GvHD (n = 3)
Complication associated with aGvHD (n = 1)
Upper GI hemorrhage
Sepsis (Enterococcus faecium) (n = 1)
Mediastinitis (n = 1)
Thrombotic microangiopathy (n = 1)
Acute kidney injury (n = 1)

b

Completed all planned study visits (n = 2)
Day 15 (n = 3)
Day 43 (n = 2)
Day 71 (n = 2)
Day 99 (n = 2)
6-month follow-up visit (n = 2)
Did not complete all planned study visits (n = 6)

Completed study drugc
(n = 2)

a

Completed all planned study visits (n = 0)b
Day 15 (n = 8)
Day 43 (n = 4)
Day 71 (n = 2)
Day 99 (n = 2)
6-month follow-up visit (n = 0)
Did not complete all planned study visits (n = 9)

c

Completed study drug
(n = 2)

Extension visit (n = 1)e
Two doses of vedolizumab 600 mg

a,d

Deaths (n = 1)
Acute myeloid leukemia

Fig. 1 Flow diagram of participants. Data presented are from the
safety analysis set. aNo deaths were considered related to study drug
by the investigator. bCompleted all planned study visits includes
participants who completed all protocol required assessments and
did not discontinue the study early. cCompleted study drug includes
participants who completed all ﬁve planned doses. dAn additional
participant in the vedolizumab IV 300 mg group died after the end of
the treatment-emergent period (i.e., 18 weeks after the last dose of
study drug). eUpon review and agreement by the medical monitor,
participants who responded to and tolerated all ﬁve planned doses of

Deaths (n = 1)a
Peritonitis (n = 1)

vedolizumab and who developed recurrent symptoms of intestinal
aGvHD following discontinuation of therapy (i.e., after the ﬁfth
dose) could enter an extension phase to receive vedolizumab 300 mg
every 2 weeks for two doses followed by every 4 weeks for up to
1 year from the ﬁrst dose of study drug. A dose other than 300 mg
and/or a frequency of administration other than every 4 weeks may
have been chosen based on accumulating safety, tolerability, efﬁcacy, and pharmacokinetic results. aGvHD acute graft-versus-host
disease, IV intravenous.

Vedolizumab for the treatment of steroid-refractory intestinal aGvHD
Table 1 Baseline characteristics.
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Table 1 (continued)

Number of participants n, (%)

Number of participants n, (%)

Vedolizumab Vedolizumab Total
300 mg
600 mg
(N = 17)
(n = 8)
(n = 9)

Vedolizumab Vedolizumab Total
300 mg
600 mg
(N = 17)
(n = 8)
(n = 9)

Age (years)a

CMV IgG antibody mismatch, donor/recipient

Mean (SD)

54.1 (10.45)

59.0 (10.87)

56.7 (10.64)

Positive/positive

2 (25.0)

1 (11.1)

3 (17.6)

Minimum,
maximum

40, 74

34, 70

34, 74

Positive/negative

2 (25.0)

2 (22.2)

4 (23.5)

Negative/positive

2 (25.0)

2 (22.2)

4 (23.5)

Negative/negative

2 (25.0)

4 (44.4)

6 (35.3)

Sex, n (%)
Male

2 (25.0)

5 (55.6)

7 (41.2)

Female

6 (75.0)

4 (44.4)

10 (58.8)

ECOG performance status n, (%)

b

0

2 (25.0)

1

3 (37.5)

2
3

2 (11.8)

a

2 (22.2)

5 (29.4)

b

1 (12.5)

4 (44.4)

5 (29.4)

2 (25.0)

3 (33.3)

5 (29.4)

4
aGvHD characteristics, grade
Grade A

0

0

CMV cytomegalovirus, ECOG Eastern Cooperative Oncology Group,
IgG immunoglobulin G, GI gastrointestinal, GvHD graft-versus-host
disease, HLA human leukocyte antigen, SD standard deviation.

0

0

c

0

0

0

Grade B

2 (25.0)

3 (33.3)

5 (29.4)

Grade C

4 (50.0)

4 (44.4)

8 (47.1)

Grade D

2 (25.0)

2 (22.2)

4 (23.5)

aGvHD characteristics, involvements
Intestinal only

7 (87.5)

5 (55.6)

12 (70.6)

Skin and intestinal

1 (12.5)

3 (33.3)

4 (23.5)

1 (11.1)

1 (5.9)

Liver and intestinal

0

Skin, liver, and
intestinal

0

0

Age at the date of informed consent.

(0) Fully active, able to carry on all predisease performance without
restriction, (1) restricted in physically strenuous activity, but
ambulatory and able to carry out work of a light or sedentary nature
(e.g., light housework, ofﬁce work), (2) ambulatory and capable of all
self-care, but unable to carry out any work activities, up and about
more than 50% of waking hours, (3) capable of only limited self-care,
conﬁned to bed or chair more than 50% of waking hours, (4)
completely disabled, cannot carry on any self-care, totally conﬁned to
bed or chair.

c
Grades were derived using the Blood and Marrow Transplant Clinical
Trials Network (BMT CTN)-modiﬁed International Blood and
Marrow Transplant Research (IBMTR) database index.
d

Stage is based on aGvHD clinical stage criteria (Supplementary
Table 3).

0

summary of the main participant characteristics and outcomes are outlined in Fig. 2.

0

Discontinuation of study drug

aGvHD characteristics, GI tractd
Stage 0

0

0

Stage 1

1 (12.5)

3 (33.3)

Stage 2

1 (12.5)

Stage 3

4 (50.0)

4 (44.4)

8 (47.1)

Stage 4

2 (25.0)

2 (22.2)

4 (23.5)

Myeloablative
transplant

4 (50.0)

3 (33.3)

7 (41.2)

Non-myeloablative
or reduced-intensity
transplant

4 (50.0)

6 (66.7)

10 (58.8)

Bone marrow

1 (12.5)

1 (11.1)

2 (11.8)

Peripheral blood

7 (87.5)

8 (88.9)

15 (88.2)

Matched

6 (75.0)

6 (66.7)

12 (70.6)

Mismatched

1 (12.5)

1 (11.1)

2 (11.8)

Haploidentical

1 (12.5)

2 (22.2)

3 (17.6)

0

4 (23.5)
1 (5.9)

Conditioning regimen

Stem cell source

HLA compatibility

Thirteen participants (76.5%) discontinued the study drug
prematurely (Fig. 1). Five of these 13 participants
(38.5%) discontinued due to progression of aGvHD (n =
1) or because of an unsatisfactory therapeutic response
(n = 4). Four participants (30.8%) discontinued owing to
‘other’ reasons, including death (n = 3) and withdrawal
(n = 1), three participants (23.1%) owing to a TEAE
(thrombotic microangiopathy, acute respiratory distress
syndrome, and adverse event, none of which were
vedolizumab-related), and one participant (7.7%) owing
to progression of an underlying malignancy (relapse of
acute myeloid leukemia).
Of those who discontinued for reasons other than unsatisfactory therapeutic response or progression of aGvHD
(n = 8), at the last study assessment only two were recorded
as having no intestinal aGvHD involvement, suggesting that
most had not responded to treatment at the time that they
discontinued the study drug.
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Baseline
Number of intestinal
doses aGvHD grade

600 mg

Participant

300 mg

Baseline
intestinal
aGvHD stage
A

3

B

3

0b
0c
a

e

5

C

5

C

C

2

4

B

D

1

3

B

E

4

1

D

1

F

4

1

D

G

3

1

C

H

3

1

C

I

4

7

D

J

1

Vedolizumab dosing

5

B

K

1

Survival after last dose of vedolizumab
Intestinal aGvHD stagee

3

B

L

4

Alive at the end of the study

3

D

M

1

2

B

2

C

2

C

2

C

1

C

N

3

O

3

P

3

Q

3
–20 –10

Death
Death due to aGvHD
AML or related precursor neoplasm
Mature B-cell neoplasm
Myelodysplastic/myeloproliferative neoplasm
Myelodysplastic syndrome
Precursor lymphoid neoplasm
Other
0

10

20

30

40

50

60

70

80

90 100 110 120 130 140 150 160 170 180 190 200

Duration on study (days)

Fig. 2 Duration of vedolizumab treatment, survival following ﬁnal
vedolizumab dose, and participant characteristics. Data presented
are from the efﬁcacy analysis set. aIntestinal aGvHD stages (based on
aGvHD clinical stage criteria) are indicated by blue circles and dashed
trace (uppermost circle aGvHD stage 4; lowermost circle aGvHD stage
0) positioned on the day that the aGvHD assessment was performed.
Stage 0 no intestinal tract involvement, Stage 1 > 500 mL diarrhea/day,

Stage 2 > 1000 mL diarrhea/day, Stage 3 > 1500 mL diarrhea/day,
Stage 4 severe abdominal pain with or without ileus. bday 255. cday
276. dParticipant C was alive at the end of the study and on day 239
experienced recurrence of intestinal aGvHD at Stage 1. eday 239.
aGvHD acute graft-versus-host disease, AML acute myeloid leukemia,
GvHD graft-versus-host disease.

Overall response

Overall survival
At 6 months, ﬁve of the 17 participants (29.4%) were
alive: four (50%; 4 of 8) in the vedolizumab 300 mg and
one (11.1%; 1 of 9) in the vedolizumab 600 mg group,
with a median overall survival of 161 days (range,
16–310 days) in the 300 mg group and 58 days (range,
24–189 days) in the 600 mg group (Fig. 4). At the time of
study termination, three participants were alive, all

Proportion of participants (%)

100

At day 28, a total of six participants (35.3%) had an OR in
all organs involved, and six of the eight participants with an
OR in intestinal aGvHD at day 28 experienced a durable
response (response maintained through day 43). An OR in
intestinal aGvHD was recorded in 11 participants (64.7%)
and eight participants (47.1%) at day 15 and day 28,
respectively (Fig. 3). A complete response in all organs
involved was reported in two participants at day 15, in one
at day 28, and in four at day 43.

11/17

6/17

8/17

9/17

64.7%

35.3%

47.1%

52.9%

Responder

Nonresponder

Responder

Nonresponder

80
60
40
20
0

Day 15

Day 28

Fig. 3 Proportion of participants with intestinal overall response at
day 15 and day 18. Error bars represent 95% conﬁdence interval of
percentage of responders. Participants with missing data for endpoint
determination were categorized as non-responders.

from the 300 mg group. Owing to the early termination
of the study, overall survival at 12 months was not
determined.

Vedolizumab for the treatment of steroid-refractory intestinal aGvHD
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1.0
Vedolizumab 300 mg
Vedolizumab 600 mg
0.8
Probability of survival

Censored
0.6

0.4

0.2

0
0

30

60

90

120

150

180

210

240

270

300 310

Duration on study (days)
Numbers of participants at risk
300 mg

8

5

5

5

5

4

4

3

3

2

1

600 mg

9

8

4

3

2

1

1

0

0

0

0

Fig. 4 Kaplan–Meier estimates of overall survival. Data presented
are from the efﬁcacy analysis set. Overall survival was deﬁned as the
time from the date of enrollment to the date of death. Participants

without documentation of death at the time of analysis were censored
at the date last known to be alive.

Mean serum concentration (µg/mL)

Vedolizumab 300 mg
Vedolizumab 600 mg

250
200
150
100

50

10
1

10

20

30

40

50

60

70

80

90

100

Duration on study (days)

Number of participants
Day 1

Day 15

Day 43

Day 71

Day 99

16

12

8

5

4

Fig. 5 Mean serum vedolizumab concentration–time proﬁles following multiple IV infusions of vedolizumab 300 or 600 mg
delivered over 30 min (semi-log scale). Data presented are from the
pharmacokinetics analysis set (n = 16, eight participants from 300 and

600 mg dosing groups; participant N was excluded from the PK analysis set). The lower limit of quantiﬁcation is 0.2 μg/mL. The concentrations below the limit of quantiﬁcation are included as 0.
Anomalous concentrations are excluded.

Pharmacokinetics

still met the target concentration level of 10 µg/mL for
participants with inﬂammatory bowel diseases [32, 33].

In general, exposure to vedolizumab was higher over time
in participants receiving vedolizumab 600 mg compared
with those receiving vedolizumab 300 mg and was comparable with that observed in previous multiple-dose PK
studies in participants with ulcerative colitis and Crohn’s
disease [31, 32]. Serum vedolizumab Cmax was similar on
all dosing days, whereas serum vedolizumab Ctrough was
variable, with no clear trends over time or between groups
(Fig. 5). Ctrough levels were lower in the 600 mg group
versus the 300 mg group, but average Ctrough concentrations

Safety, tolerability, and treatment-emergent
adverse events
An overview of TEAEs is presented in Supplementary
Table 6. All participants in the study experienced at least
one TEAE. A total of 50 serious adverse events were
experienced by 15 participants (88.2%), most of which
(n = 46 [92.0%]) were considered unrelated to the study
drug. Overall, ﬁve participants (29.4%) experienced a
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TEAE, and two participants (11.8%) experienced a serious
adverse event considered to be related to the study drug.
The most frequently reported adverse events were
infections occurring in 15 participants (88.2%), including
three participants (17.6%) with sepsis and four participants
(23.5%) with cytomegalovirus (CMV) related infections, of
which two (11.8%) were CMV colitis. The events of CMV
colitis were both serious and considered related to the study
drug for one participant (vedolizumab 600 mg). Commonly
occurring infection-related TEAEs are presented in Supplementary Table 7.
No participants had detectable anti-vedolizumab antibodies at any scheduled time point.

Deaths
During the TEAE reporting period, 13 participants (76.5%)
died (Fig. 1). An additional participant died after the
reporting period for TEAEs (18 weeks after the last dose of
study drug). No deaths were considered by the investigator
to be related to the study drug. The most common causes of
death were attributed to complications associated progression of aGvHD (n = 5) or sepsis (n = 3). Other causes of
death in the remaining participants (n = 5) who died during
the TEAE period were due to the development of peritonitis
(percutaneous endoscopic gastrostomy probe placement
related), thrombotic microangiopathy, mediastinitis, or
acute kidney injury; one cause of death was not reported.
The death of the participant after the TEAE period was due
to a fatal relapse of acute myeloid leukemia. Additional
details at the time of death for each participant are provided
in Table 2.

Discussion
The primary objective of this phase 2a study was to characterize the efﬁcacy, tolerability, and safety of vedolizumab
to identify a recommended dose for further evaluation of the
treatment of SR intestinal aGvHD. While early clinical
beneﬁt (64.7% OR rate at day 15) was observed in
approximately two-thirds of participants, less than half
obtained an OR in intestinal aGvHD by day 28, with a
signiﬁcant number (n = 8) of participants dying from
complications of aGvHD. An early review (prior to day 28)
of patient-level data for the 17 enrolled participants concluded that the expected efﬁcacy outcome for the study
would not be achieved and the decision was made to terminate the study prior to completion of planned enrollment.
There are a number of potential reasons for the lack of a
satisfactory OR in this study. Most notably, all participants
had SR aGvHD with lower intestinal involvement, with a
strict deﬁnition of SR, and approximately 70% had severe
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GI (Stage 3: 47.1%; Stage 4: 23.5%). Moreover, more than
70% of participants had SR Grade C or D aGvHD, and
~30% had multiorgan involvement at baseline. Among
patients with aGvHD intestinal tract involvement, GI Stage
3–4 and SR aGvHD in particular are associated with substantial morbidity and mortality, with a signiﬁcantly
increased risk of infections, and a limited response to salvage therapies [5, 34–38]. The signiﬁcant complications
inherent in patients with such disease, including early death
and premature discontinuation of study drug, can possibly
impair the ability to evaluate efﬁcacy compared with other
SR aGvHD studies, which have included patients without
intestinal involvement.
Given the data from this study, it is also certainly possible that treatment with vedolizumab was unable to exert
an effect rapid enough and/or of signiﬁcant magnitude to
allow the injured GI epithelium to recover sufﬁciently and
prevent disease-related complications. It has been proposed
that if enough tissue injury has occurred, T-cell migration to
the GI endothelium is of limited importance, and α4β7
integrin is no longer needed for the propagation of aGvHD
[39]. From this perspective, vedolizumab might not be
expected to exert a signiﬁcant therapeutic effect in advanced
disease. This hypothesis is supported by a recent study by
Fu et al., which highlighted the key role played by the
α4β7-MAdCAM-1 interaction in the early recruitment of
donor T cells to the intestinal stem cell compartment [40].
Therefore, vedolizumab may have greater therapeutic beneﬁt if administered as initial or preventative therapy.
A number of case series on the use of vedolizumab in SR
intestinal aGvHD have reported variable outcomes
[9, 26, 39, 41, 42]. Fløisand et al. initially reported a 100%
OR rate in six patients with SR intestinal aGvHD treated
with vedolizumab 300 mg, with two deaths (due to sepsis/
acute respiratory distress syndrome and multiorgan failure)
after a median follow-up time of 10 months [26]. Contrastingly, Bukauskas et al. reported ﬁve patients with SR
aGvHD with intestinal involvement who were treated with
vedolizumab and who died at a median of 32 days (range,
7–172 days) after starting therapy. All deaths were attributed to infectious complications with persistent aGvHD
symptoms. Partial responses were observed in only two
patients [41]. Similarly, Coltoff et al. reported high mortality rates in a retrospective case series of nine patients with
SR intestinal aGvHD treated with vedolizumab 300 mg,
with only one patient surviving beyond 60 days, with most
patients dying of infection [42].
There have been two recent large retrospective multicenter case series published. Danylesko et al. described
29 patients with SR intestinal aGvHD treated with vedolizumab IV 300 mg and demonstrated OR rates of 79%
(28% complete response, 52% partial response) after
7–10 days. Twelve patients (41%) were able to discontinue
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immunosuppressive therapy. Overall survival rates at 6 and
12 months were 41.4% and 27.5%, respectively, with the
majority of successful outcomes observed in patients who
were treated early in their disease course [39]. Fløisand
et al. described a series of 29 patients with SR aGvHD
treated with vedolizumab, reporting an OR rate of 64%
(6–10 weeks after initiation of drug) and a 6-month overall
survival rate of 54% [9].
Taken together, the early OR results observed in this
study, along with the anecdotal evidence from retrospective
case studies, justify pursuing the evaluation of vedolizumab
for lower intestinal SR GvHD. However, considering the
mechanism of action and kinetics of GI epithelial regeneration in the context of aGvHD, vedolizumab may be more
effective if administered earlier in the disease course, such
as for prevention, pre-emptive use, or initial therapy.
With regard to safety, observed adverse events were
comparable with prior reports in a patient population with
SR GvHD [43]. The mortality rate observed in this trial was
comparable to historical series of patients with SR aGvHD
with intestinal involvement [44, 45]. In the current study, no
safety signals were identiﬁed that were associated with the
use of either dose of vedolizumab, and the reported adverse
events were not related to immunogenicity because all
participants were negative for anti-vedolizumab antibodies.
Overall, this study was unable to demonstrate a positive
proof-of-concept in efﬁcacy in participants with SR GvHD
treated with vedolizumab. While early and durable responses
to intestinal aGvHD following treatment with vedolizumab
were observed in some participants, vedolizumab was unable
to generate a satisfactory response in this study. Evaluating
the true efﬁcacy of vedolizumab in patients with advanced
severe intestinal aGvHD and associated complications is
clearly challenging and perhaps not realistically possible. It
may be that vedolizumab may be more suited to use for
intestinal GvHD prevention, and this is currently being
evaluated in a phase 3 clinical trial (NCT03657160).
The observations made in this study are nevertheless
important, as they provide vital information on the severity
of SR intestinal aGvHD and management of complications
that need to be considered when designing and conducting
future studies in such patients if positive efﬁcacy outcomes
are to be demonstrated.

Data availability
Data pertaining to this study and the associated study protocol may be found at ClinicalTrials.gov (identiﬁer:
NCT02993783). Reuse of these data is not permitted.
Additional data that support the ﬁndings of this study are
available from Takeda Pharmaceuticals International upon
reasonable request.
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